公开(公告)号：US20200010426A1

公开(公告)日：2020-01-09

申请号：US16571405

申请日：2019-09-16

Applicant: Novartis AG

Inventor： Daniela Angst ,  Francois Gessier ,  Anna Vulpetti

IPC: C07D239/47 ,  A61K31/506 ,  A61K31/505 ,  A61P35/02 ,  A61P29/00 ,  C07D405/12 ,  C07D401/12 ,  C07D401/10 ,  C07D401/14 ,  C07D403/12

Abstract: The present invention describes new amino pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.

公开(公告)号：US09464081B2

公开(公告)日：2016-10-11

申请号：US14409878

申请日：2013-06-27

Applicant: Novartis AG

Inventor： Stefanie Flohr ,  Ulrich Hommel ,  Edwige Liliane Jeanne Lorthiois ,  Jeurgen Klaus Maibaum ,  Nils Ostermann ,  Jean Quancard ,  Stefan Andreas Randl ,  Olivier Rogel ,  Anna Vulpetti

IPC: C07D471/04 ,  C07D403/14 ,  C07D403/06 ,  C07D403/12

CPC classification number: C07D471/04 ,  C07D403/06 ,  C07D403/12 ,  C07D403/14

Abstract: The present invention provides a compound of formula (I) a method for manufacturing the compounds of the invention, and its therapeutic uses as a factor D inhibitor for the treatment of ophthalmic diseases. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

公开(公告)号：US20240216513A1

公开(公告)日：2024-07-04

申请号：US18281732

申请日：2022-03-10

Applicant: Novartis AG

Inventor： Claire Adcock ,  Valerie Broennimann ,  Jiashun Cheng ,  Rohit Kumar Duvadie ,  Tanzina Fazal ,  Jinhai Gao ,  Fengfeng Guo ,  Robert Martin Grotzfeld ,  Christina Hebach ,  Gregory John Hollingworth ,  Darryl Brynley Jones ,  Alexei Karpov ,  Jialiang Li ,  Julien Lorber ,  Chester A. Metcalf, III ,  Walter Michael ,  Mark Gabriel Palermo ,  Scott Vaughan Plummer ,  James Harold Roache ,  Martin Sendzik ,  Ranny Mathew Thomas ,  Aimee Richardson Usera ,  Anna Vulpetti ,  Frederic Zecri ,  Liang Zhao ,  Thomas Zoller

IPC: A61K47/54 ,  A61K31/395 ,  A61K47/10 ,  A61P35/00

CPC classification number: A61K47/542 ,  A61K31/395 ,  A61K47/10 ,  A61P35/00

Abstract: Described herein are fatty acid-bifunctional degrader compounds, their various targets, their preparation, pharmaceutical compositions comprising them, and their use in the treatment of conditions, diseases, and disorders mediated by various target proteins.

公开(公告)号：US11541056B2

公开(公告)日：2023-01-03

申请号：US16981208

申请日：2019-03-25

Applicant: NOVARTIS AG

Inventor： Luca Arista ,  Christina Hebach ,  Gregory John Hollingworth ,  Philipp Holzer ,  Patricia Imbach-Weese ,  Rainer Machauer ,  Niko Schmiedeberg ,  Anna Vulpetti ,  Thomas Zoller

IPC: C07D519/00 ,  C07D487/04 ,  A61K31/519 ,  A61P35/00

Abstract: The invention relates to compounds of the formula (I) or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined in the specification; to intermediates in the preparation of the compounds, to pharmaceutical compositions comprising the compounds and to use of the compounds in the treatment of disease.

公开(公告)号：US20150166578A1

公开(公告)日：2015-06-18

申请号：US14409882

申请日：2013-06-27

Applicant: NOVARTIS AG

Inventor： Eva Altmann ,  Ulrich Hommel ,  Edwige Liliane Jeanne Lorthiois ,  Jeurgen Klaus Maibaum ,  Nils Ostermann ,  Stefan Andreas Randl ,  Olivier Rogel ,  Anna Vulpetti

IPC: C07F7/08 ,  C07D403/12 ,  C07D403/14 ,  C07D403/06 ,  C07D471/04

CPC classification number: C07F7/0812 ,  C07D403/06 ,  C07D403/12 ,  C07D403/14 ,  C07D471/04

Abstract: The present invention provides a compound of formula (I) a method for manufacturing the compounds of the invention and its therapeutic uses as complement pathway modulators for the treatment of ocular diseases. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Abstract translation: 本发明提供式（I）化合物，其是制备本发明化合物的方法及其作为治疗眼部疾病的补体途径调节剂的治疗用途。 本发明还提供药理活性剂和药物组合物的组合。

公开(公告)号：US20150148374A1

公开(公告)日：2015-05-28

申请号：US14409914

申请日：2013-06-27

Applicant: NOVARTIS AG

Inventor： Ulrich Hommel ,  Edwige Liliane Jeanne Lorthiois ,  Jeurgen Klaus Maibaum ,  Nils Ostermann ,  Stefan Andreas Randl ,  Olivier Rogel ,  Anna Vulpetti

IPC: C07D403/14 ,  C07D471/04

CPC classification number: C07D403/14 ,  A61K31/4155 ,  A61K31/416 ,  A61K31/437 ,  A61K45/06 ,  C07D471/04 ,  A61K2300/00

Abstract: The present invention provides a compound of formula I: a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Abstract translation: 本发明提供式I化合物：制备本发明化合物的方法及其治疗用途。 本发明还提供药理活性剂和药物组合物的组合。

公开(公告)号：US09815819B2

公开(公告)日：2017-11-14

申请号：US14409871

申请日：2013-06-27

Applicant: Novartis AG

Inventor： Eva Altmann ,  Ulrich Hommel ,  Edwige Liliane Jeanne Lorthiois ,  Jeurgen Klaus Maibaum ,  Nils Ostermann ,  Jean Quancard ,  Stefan Andreas Randl ,  Olivier Rogel ,  Anna Vulpetti

IPC: C07D471/04 ,  C07D491/056 ,  C07D403/06 ,  A61K31/416 ,  A61K31/4162 ,  A61K45/06

CPC classification number: C07D403/06 ,  A61K31/416 ,  A61K31/4162 ,  A61K45/06 ,  C07D471/04 ,  C07D491/056 ,  A61K2300/00

Abstract: The present invention provides a compound of formula I: (I) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

公开(公告)号：US09550755B2

公开(公告)日：2017-01-24

申请号：US14409914

申请日：2013-06-27

Applicant: NOVARTIS AG

Inventor： Ulrich Hommel ,  Edwige Liliane Jeanne Lorthiois ,  Jeurgen Klaus Maibaum ,  Nils Ostermann ,  Stefan Andreas Randl ,  Olivier Rogel ,  Anna Vulpetti

IPC: A61K31/44 ,  C07D471/02 ,  C07D403/14 ,  A61K45/06 ,  A61K31/4155 ,  A61K31/416 ,  A61K31/437 ,  C07D471/04

CPC classification number: C07D403/14 ,  A61K31/4155 ,  A61K31/416 ,  A61K31/437 ,  A61K45/06 ,  C07D471/04 ,  A61K2300/00

Abstract: The present invention provides a compound of formula I: a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Abstract translation: 本发明提供式I化合物：制备本发明化合物的方法及其治疗用途。 本发明还提供药理活性剂和药物组合物的组合。

公开(公告)号：US09487483B2

公开(公告)日：2016-11-08

申请号：US14409911

申请日：2013-06-27

Applicant: Novartis AG

Inventor： Eva Altmann ,  Ulrich Hommel ,  Edwige Liliane Jeanne Lorthiois ,  Jeurgen Klaus Maibaum ,  Nils Ostermann ,  Jean Quancard ,  Stefan Andreas Randl ,  Olivier Rogel ,  Anna Vulpetti ,  Stefanie Flohr

IPC: C07D209/52 ,  C07D471/04 ,  C07D401/14 ,  C07D403/06 ,  C07D403/14 ,  C07D487/04 ,  A61K45/06

CPC classification number: C07D209/52 ,  A61K45/06 ,  C07D401/14 ,  C07D403/06 ,  C07D403/14 ,  C07D471/04 ,  C07D487/04

Abstract: The present invention provides a compound of formula (I): a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

公开(公告)号：US09468661B2

公开(公告)日：2016-10-18

申请号：US14409893

申请日：2013-06-27

Applicant: NOVARTIS AG

Inventor： Eva Altmann ,  Ulrich Hommel ,  Edwige Liliane Jeanne Lorthiois ,  Jeurgen Klaus Maibaum ,  Nils Ostermann ,  Jean Quancard ,  Stefan Andreas Randl ,  Olivier Rogel ,  Anna Vulpetti

IPC: A61K38/05 ,  C07D403/12 ,  C07D403/06 ,  C07D403/14 ,  C07D417/14 ,  C07D471/04 ,  C07K5/062

CPC classification number: A61K38/05 ,  C07D403/06 ,  C07D403/12 ,  C07D403/14 ,  C07D417/14 ,  C07D471/04 ,  C07K5/06026

Abstract: The present invention provides a compound of formula (I) a method for manufacturing the compounds of the invention, and its therapeutic uses as complement pathway modulators for the treatment of ocular diseases. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.